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ABSTRACT
Background There is considerable interest in the use of
next-generation sequencing to help diagnose unidentified
genetic conditions, but it is difficult to predict the
success rate in a clinical setting that includes patients
with a broad range of phenotypic presentations.
Methods The authors present a pilot programme of
whole-exome sequencing on 12 patients with
unexplained and apparent genetic conditions, along with
their unaffected parents. Unlike many previous studies,
the authors did not seek patients with similar
phenotypes, but rather enrolled any undiagnosed
proband with an apparent genetic condition when
predetermined criteria were met.
Results This undertaking resulted in a likely genetic
diagnosis in 6 of the 12 probands, including the
identification of apparently causal mutations in four
genes known to cause Mendelian disease
(TCF4, EFTUD2, SCN2A and SMAD4) and one gene
related to known Mendelian disease genes (NGLY1).
Of particular interest is that at the time of this study,
EFTUD2 was not yet known as a Mendelian disease
gene but was nominated as a likely cause based on the
observation of de novo mutations in two unrelated
probands. In a seventh case with multiple disparate
clinical features, the authors were able to identify
homozygous mutations in EFEMP1 as a likely cause for
macular degeneration (though likely not for other
features).
Conclusions This study provides evidence that
next-generation sequencing can have high success rates
in a clinical setting, but also highlights key challenges.
It further suggests that the presentation of known
Mendelian conditions may be considerably broader than
currently recognised.
INTRODUCTION
Whole-genome and whole-exome sequencing have
proven remarkably successful in identifying the
causes of Mendelian diseases. These analyses have
generally depended on the availability of more than
one unrelated affected individual and/or linkage
evidence in at least one family. However, next-
generation sequencing (NGS) has also succeeded in
identifying causes of genetic conditions even when
they are seen in only a single patient.1e3
Consequently, there is growing interest in the
introduction of NGS into the clinic to aid in the
diagnosis of conditions for which no genetic cause
can be found with targeted testing or chromosomal
arrays. However, in a clinical setting, patients with
undiagnosed genetic conditions tend to present
with a wide range of clinical features, and it is often
necessary to consider each patient’s genome indi-
vidually, rather than looking for common disrupted
genes in multiple cases with a similar phenotype. It
is not clear what success rate NGS approaches will
achieve in providing genetic diagnoses in this more
challenging setting. In this study, we have evalu-
ated the use of NGS to provide genetic diagnoses
using 12 parent-child trios in which the child had
congenital anomalies and/or intellectual disabilities
due to unexplained conditions presumed to be
genetic. Importantly, the patients were chosen to
be representative of a clinical sample of undiag-
nosed genetic conditions, in that they were not
selected for genetic tractability or phenotypic
homogeneity.
METHODS
Exome sequencing was performed on each patient
and both parents using the Illumina HiSeq2000
platform and the Agilent SureSelect Human All
Exon 50Mb Kit. Detailed methods for laboratory
work can be found in the online supplementary
methods.
Study population
The research protocol was approved by the Duke
Institutional Review Board, and all human partici-
pants or their guardians gave written informed
consent. Twelve families (child, mother and father)
were recruited through the genetics clinic at Duke
University Medical Center based on whether their
child met two or more of the following criteria:
(1) unexplained intellectual disability and/or devel-
opmental delay; (2) one major congenital anomaly;
(3) 2e3 minor congenital anomalies; and (4) facial
dysmorphisms. In addition, the families were
required to meet the following eligibility require-
ments: (1) both biological parents available for
testing; (2) previous clinically indicated genetic
testing, including a chromosomal microarray
(Affymetrix 6.0, http://www.affymetrix.com),
had been normal; and (3) no evidence of effects of
teratogens, birth asphyxia or non-accidental trauma.
Subjects were not eligible if the mother was preg-
nant at the time of enrolment. Finally, results were
only returned to patients and/or patient families
following conﬁrmation of detected variants in
a CLIA certiﬁed laboratory. Controls were subjects
enrolled in Center for Human Genome Variation
studies through Duke Institutional Review Board
approved protocols (n¼830).
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Identification of potentially causal variants
Sequence Variant Analyser (SVA)4 (http://www.svaproject.org/)
was used to identify variants of interest using standard ﬁltering
criteria, (Single nucleotide variant (SNV) quality, SNV consensus
score, insertion-deletion (INDEL) consensus score $20, INDEL
quality $50, number of reads supporting SNV or INDEL $3).
We designed screens to identify highly penetrant genotypes that
might account for each child’s conditions, and prioritised vari-
ants as follows: (1) homozygous (including hemizygous X
variants) in the proband and never homozygous in the controls
(recessive and X-linked variants); (2) heterozygous in the
proband and absent in the parents and controls (putative de
novo variants); and (3) from genes with two rare (MAF<0.03)
variants in the proband that were not seen together in the
parents or in any controls (compound heterozygotes). All vari-
ants, whether annotated as functional or not, were subjected to
the screens for homozygous, X-linked and de novo candidates,
the screen for compound heterozygous variants was limited to
missense and nonsense SNVs, and frameshift INDELs. Appro-
priate functional work, where applicable, was performed based
on the annotated function of the variant (online supplementary
ﬁgure 1).
Further filtering of variants
Homozygotes
We removed any homozygous variant that was present in >3%
of controls (corresponding to a disease frequency of 1 in 4500 or
greater). For homozygous variants that were not present in the
heterozygous form in both parents, we ﬁrst removed those with
low coverage (<10 reads), and then examined raw alignments
for the remainder. In all cases, this was sufﬁcient to resolve
whether the variant was present in the parent but not called
(because of <3 reads or poor quality scores), or incorrectly called
as homozygous in the child.
De novos
Parental and proband raw alignments were examined for all
potential de novo SNVs. The majority was ruled out for one
of the following reasons: (a) low coverage in parents (<10x); (b)
variant is visibly present in parental alignments but not identi-
ﬁed by SAMtools; or (c) alignments look unconvincing (eg,
multiple mismatches in same read, variant is at the very ends of
reads) in proband and/or parents. For potential de novo INDELs,
we removed those with fewer than ﬁve variant reads or with
a variant/reference read ratio #0.3 (the vast majority) before
inspection of raw alignments.
Compound heterozygotes
Raw alignments for all potential compound heterozygous vari-
ants were inspected in the proband and parents to ensure that
the contributing variants were each inherited from a different
parent.
Communication of results to families
All families underwent genetic counselling at the time of
participation. In the initial counselling session, de novo, auto-
somal-recessive and X-linked inheritance patterns were discussed
and it was emphasised that autosomal-dominant conditions
with incomplete penetrance, synergistic heterozygosity, mito-
chondrial disorders and epigenetic changes would not be
detected with this approach. All families were aware that
a variant of interest that may be detected may not be deﬁnitely
proven casual, and also that no results may be obtained. Parents
were informed that variants of uncertain signiﬁcance would not
be reported to them. We debated if we should re-contact families
after completion of the study, in the event that a variant of
uncertain signiﬁcance was subsequently thought to be casual
but it was decided that it was not feasible to offer to do so.
Variants thought to be causal or reasonably thought to
contribute to the patient’s phenotype were conﬁrmed in a CLIA-
certiﬁed laboratory prior to communication to the families, at
which time a second genetic counselling session was arranged
for discussion of results. With the permission of the families,
the information was then communicated to the child’s
physicians.
For families wherein there would be no conclusive results,
the second counselling session would be held after completion
of the sequence data analyses. It was discussed with families
that secondary or incidental ﬁndings in the child or the parents
would not be intentionally screened for. If incidentally observed,
the only variants that would be communicated were those
within known genes that would result in premature death if
untreated. Detection of carrier status in the affected child
would not result in communication of such results. Detection of
carrier status in the parents for known genetic conditions would
be communicated to them, although it was emphasised that the
genomes would not be proactively screened for such variants.
RESULTS
Exome sequencing of each trio (table 1) resulted in an average
coverage at captured regions of 71x (table 2). We used the SVA
software,4 followed by manual inspection of candidate variants,
as described in the online supplementary methods, to screen
for candidate homozygous X-linked, compound heterozygous
and de novo variants. The SVA screening produced a list of 260
candidate de novo SNVs and 364 candidate de novo INDELs, of
which 18 SNVs (7%) and 2 INDELs (0.5%) were retained as
high-conﬁdence variants after manual inspection (table 2). Using
this screening procedure, we found a likely genetic diagnosis in
six of the families, a likely explanation for one of the clinical
features in a seventh subject and a number of suggestive muta-
tions in other families. No secondary (incidental) variants were
detected in the probands or their parents.
Likely genetic diagnosis: Trios 1 and 7dEFTUD2
Depending on how ‘functional’ mutations are deﬁned, sequencing
studies suggest an average of about one functional de novo
mutation per genome.5 In this study, we see a total of 20 high-
conﬁdence de novo variants, somewhat higher than reported
for controls.6 A particularly striking observation is that of these
20 de novo putatively functional variants, two were observed in
the same gene, EFTUD2, in trio 1 and trio 7. Both variants were
conﬁrmed as de novo with Sanger sequencing. Very approxi-
mately, assuming (incorrectly) that each gene of the approxi-
mately 22 000 captured is equally likely to harbour a de novo
mutation, the likelihood of seeing the same gene affected by
chance in 2 of 20 de novos is 0.0086, suggesting the possibility
of involvement of EFTUD2 in these patients’ conditions. The
patients share some clinical features (table 3), although they
were not originally considered to be similar.
The variant in trio 1 is a G/A transition located at the +5
position in the splice donor site of exon 11. G>A mutations
of the +5G have been observed in several human inherited
disorders,7e9 and in some studied examples site-directed muta-
genesis of the +5G results in reduced splicing efﬁciency.10e12
Investigation of the mRNA isolated from blood of the proband
and parents did not detect altered splicing or expression level,
but tissue-speciﬁc impaired splicing remains a possibility.
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Documentation of a functional effect on splicing will be
required to conﬁrm pathogenicity of this variant. The EFTUD2
variant in trio 7 is a frameshift INDEL causing the premature
termination of the protein at the end of exon 9 (residue 222/
962). This study thus identiﬁed EFTUD2 as a leading candidate
for explaining the conditions in these children. Subsequent to
this work, Lines and colleagues13 very recently reported an
analysis of 12 patients with Mandibulofacial Dysostosis with
microcephaly, and found that all have de novo mutations in
EFTUD2. On examination, both these patients show similarities
to the children in this report, and the patient from trio seven
ﬁts the condition very closely.
Trio 2: NGLY1
Screening for compound heterozygous variants revealed that
patient 2 had inherited a frameshift variant in the last exon of
NGLY1 from his mother, and a nonsense mutation in exon 8
from his father. NGLY1 encodes N-glycanase 1, which is involved
in the degradation of misfolded glycoproteins. N-glycanase 1 has
not been associated with a speciﬁc disorder, but the phenotype
of this child is consistent with a congenital disorder of glyco-
sylation (table 1), and transferring isoelectric focusing and
N-glycan analyses have been normal on repeated testing. To
further explore the effect of these variants, we compared NGLY1
protein expression in leucocytes extracted from blood from the
patient, his parents and three controls. Both parents showed
reduced expression compared with controls, and the patient had
barely discernible levels of NGLY1 (ﬁgure 1). Dysfunction of
NGLY1 would be expected to result in abnormal accumulation
of misfolded glycoproteins due to impaired degradation. In our
patient, liver biopsy showed an amorphous unidentiﬁed substance
throughout the cytoplasm, suggestive of stored material in the
liver cells. It is to be noted that extensive testing for lysosomal
storage had also been pursued in this child, and all the results had
been normal. Further cellular assays are underway to better
characterise this mutation.
Trio 3: SMAD4
A de novo non-synonymous mutation was identiﬁed in SMAD4
in trio 3, resulting in an isoleucine to valine substitution at
amino acid position 500 (I500V). This variant has recently been
reported to be the causal variant in approximately half of all
Table 1 Demographic and clinical features of sequenced patients
Trio Sex Age Race Symptoms
Genetic tests performed clinically
before enrolment in study
1 M 8 Indian Developmental delay, possible autism, microcephaly,
dysmorphic features, spine abnormalities, sensorineural
hearing loss
Chromosome microarray (paternally inherited 15q13.3
dup), Fragile X
2 M 3 European-American Developmental delay, multifocal epilepsy, involuntary
movements, abnormal liver function, absent tears
Chromosomes, chromosome microarray, Niemann-Pick
type C, hepatocerebral mDNA depletion panel (POLG1,
DGUOK, MPV17), ataxia with oculomotor apraxia type 2
(SETX), Allgrove Syndrome, ataxia telangectasia (ATM),
Rett (MECP2), alphad1 antitrypsin (AAT), congenital
disorder of glycosylation (transferrin isoelectric focusing
and N-glycan analysis), metabolic tests (Tay Sachs,
Sandhoff, mannosidosis, mucolipidosis II, Krabbe,
metachromatic leukodystrophy, adrenoleukodystrophy,
GAMT, plasma amino acids, plasma acylcarnitine, urine
organic acids).
3 M 3 European-American Developmental delay, autism, coarctation of the aorta,
tethered cord, congenital nystagmus and strabismus
Chromosome microarray (maternally inherited 15q26.3
deletion), Smith-Lemli-Opitz, Aarskog
4 F adult European-American multiple congenital abnormalities and macular degeneration Chromosome microarray (2 stretches of loss of
heterozygosity on chromosome 2), Fragile X
(premutation carrier)
5 F 12 European-American Severe intellectual disability, autism, bilateral hyperpronated
feet, facial dysmorphisms
Chromosomes, chromosome microarray, Rett, Angelman
methlyation, Fragile X, Cohen Syndrome
6 M 18 European-American Intellectual disability, epilepsy, panhypopituitarism,
hypertension, bifid great toe, vertebral segmentation
anomalies and sagittal cleft of the vertebra, hypoplastic 13th
rib, and delayed bone age
Chromosomes, chromosome microarray, Borgeson-
Forssman-Lehman syndrome
7 M 2 European-American Microcephaly, facial asymmetry, acyanotic Tetralogy of
Fallot; history of small muscular ventricular septal defect;
right aortic arch with mirror image branching; malformed
right ear with hearing loss, bifid uvula, cleft soft palate
Chromosome microarray, CHARGE (CHD7)
8 M 16 European-American Severe intellectual disability, dysmorphic features evident,
bicuspid aortic valve, bilateral coronal craniosynostoses,
quadriplegic cerebral palsy, bilateral inguinal hernias, G-tube
placement and obstructive sleep apnoea
Chromosome microarray, craniosynostosis syndromes
(FGFR2), non-syndromic craniosynostosis (FGFR3)
Saethre-Chotzen syndrome (TWIST)
9 F 4 Algerian Developmental delay, bilateral congenital cataracts and
strabismus, ventricular and atrial septal defects, a unilateral
clubfoot, and unilateral choanal atresia
Chromosome microarray (Long stretch of loss of
heterozygosity on chromosome 17), CHARGE (CHD7),
PAX6, 7-dehydrocholesterol and cholesterol levels
10 M 11 European-American Attention deficit hyperactivity disorder, language delays,
coarse facial features, bilateral mandibular cysts, low muscle
tone
Chromosome microarray, Costello (H-RAS), Gorlin
(PTCH), Comprehensive Noonan sequencing array
(BRAF, HRAS, KRAS MAPT2K1, MAPTK2, PTPN11,
RAF1, SHOC2 and SOS1), MPS panel
11 M 9 European-American Severe intellectual disability, developmental delay, seizures/
infantile spasms, hypotonia and minor dysmorphisms
Chromosomes, chromosome microarray (familial Xp11.4
duplication), acylcarnitine profile, plasma amino acids,
urine organic acids, creatine/guanidinoacetate analysis in
urine and blood
12 F 4 European-American Speech delay, borderline microcephaly, failure to thrive,
dysplastic nails, ventricular septal defect and hip dysplasia
Chromosomes, chromosome microarray
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cases of Myhre syndrome, a clinically heterogeneous and rare
developmental disorder. All other cases in these reports were
caused by substitutions at the same position, including ile500thr
and ile500met. Myrhe syndrome is characterised by variable
short stature, short hands and feet, facial dysmorphisms,
muscular hypertrophy, skin thickening, joint limitation, deaf-
ness and cognitive delay.14e16 Our patient did not present as
a typical case. Although he has hearing loss, cognitive impair-
ment and some of the characteristic facial dysmorphisms as
well as ocular anomalies and congenital heart defects, he lacks
some key diagnostic features including short stature, muscular
hypertrophy, joint limitation, skin thickening and skeletal
abnormalities. However, he is much younger than most reported
patients, and it is possible that some manifestations such as
joint stiffness, muscular hypertrophy and the skin thickening
may emerge later. He also has scoliosis, which has not previously
been described as a feature of Myhre syndrome. This case
illustrates that with NGS, more early diagnoses and detection
of patients with atypical presentations of Mendelian disorders
would occur, resulting in widening of the phenotypic spectrum
of these disorders.
Trio 5: TCF4
A novel de novo mutation was found in TCF4, a gene known to
carry mutations responsible for Pitt-Hopkins syndrome (PHS).
Sanger sequencing conﬁrmed that the mutation is de novo, and
a TaqMan assay in 1298 controls found no other carriers. We
then evaluated the mRNA of the trio and found that the variant
destroys the 39 splice site of exon 9 (655 G>A, D219N), resulting
in the incorporation of 37 incorrect amino acids before intro-
duction of a stop codon and premature termination. Examina-
tion of protein expression showed that the variant protein was
completely degraded through the ubiquitin-proteasome system
(ﬁgure 2). This is likely to lead to haploinsufﬁciency of TCF4, the
known cause of PHS.
In retrospect, our patient’s features of wide mouth, high
cheekbones, deep-set eyes, limited speech and severe intellectual
disabilities, are consistent with a diagnosis of PHS. She lacks
the characteristic hyperventilation (seen in 86% of reported
cases) and epilepsy (70%).17 Due to the absence of both these
distinctive features, she had not been tested for this disorder,
although it had been considered in the differential diagnosis.
Trio 11: SCN2A
A de novo variant was identiﬁed in SCN2A, a neuronal voltage-
gated sodium channel gene. The mutation was at a site for
which no previous mutation had been reported. Approximately
20 de novo and inherited variants in SCN2A have been reported
to cause seizure disorders, mostly mild but occasionally
accompanied by severe intellectual disabilities including
infantile epilepsy.18e30 This non-synonymous SCN2A variant,
Asp1598Gly, has a PolyPhen score of 0.99 (range 0e1), meaning
that it is very likely to be detrimental to the protein,31 and was
conﬁrmed to be de novo by Sanger sequencing. Residue Asp1598
is located in transmembrane segment D4S3 of sodium channel
Table 2 Exome sequencing quality and summary of rare homozygous and de novo variants
Trio
Coverage proband Coverage mother Coverage father
Rare
homo X-linked
Cpd
hets
de novos
Variants
of interest
Captured
regions with
coverage
>10 (%)
Average
coverage
captured
regions
Captured
regions with
coverage
>10 (%)
Average
coverage
captured
regions
Captured
regions with
coverage
>10 (%)
Average
coverage
captured
regions
Confirmed
by Sanger
sequencing/
TaqMan
Not confirmed
but high
coverage,
good quality
alignment
1 89.8 115 90.19 64 90.59 65 25 17 0 EFTUD2 i-e ZPF90 NS,
TMEM175 S
EFTUD2
2 88.9 63 87.5 60 88.37 58 6 9 2 none NGLY1
3 88.2 58 85.2 48 86.29 45 9 6 0 SMAD4 NS NTSR1 NS,
AC121493.1
NS
SMAD4
4 91.5 80 88.34 72 90.85 73 15 NA 0 AT6AP2 NS EFEMP1
5 90.1 64 90.67 71 91.02 67 7 NA 1 TCFA NS RBM43 NS TCFA
6 88.9 60 87.18 102 89.07 61 16 6 0 HNRNPU
ESS
SMAD1, NS HNRNPU,
SMAD1
7 87.3 68 89.75 87 90.33 94 7 8 0 EFTUD2
FS
EFTUD2
8 85.9 55 89.72 81 92.39 106 3 4 0 None
9 89.3 57 80.68 100 85.63 60 36 NA 0 ZNF266 S,
C12OR51 NS,
SAMD13 FS
None
10 90.8 72 90.59 68 78.37 83 6 5 0 MAST1 NS
11 91.6 88 89.54 67 89.22 71 8 5 1 SCN2A NS TBC1D1 NS SCN2A
12 91.0 77 90.61 68 90.33 71 4 NA 0 NR1H3 NS,
AP4M1 in
None
1¼percentage of captured regions with coverage>5; 2¼average coverage captured regions (x); NS, non-synonymous, S, synonymous; i-e, intron-exon boundary; in, intronic variant; FS,
frameshift variant; ESS, change in essential splice site.
Table 3 Clinical features of the two patients with EFTUD2 mutations,
demonstrating similarities and dissimilarities between the two
Case 1 Case 7
Developmental delay Yes Yes
Microcephaly Yes Yes
Vertebral anomalies Yes - fusion of C2 to
C5 vertebrae
None
Hearing loss Yes - sensorineural hearing
loss on both sides
Hearing loss on
the right side
Auricles Abnormal Abnormal
Limbs Hypoplastic right thumb/limited
flexion and extension of the right
interphalangeal thumb joint
Normal
Palate Normal Soft cleft palate
Cardiac anomaly None Tetralogy of Fallot
Facial asymmetry None Yes
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Nav1.2, within the sequence WNIFDF that is highly conserved
in mammalian and invertebrate voltage-gated sodium channels
(ﬁgure 3). In the bacterial sodium channel, the corresponding
sequence is WSLFDF, and the recently determined crystal
structure indicates that this aspartate residue (D80) can form a
hydrogen bond with a positive (arginine) gating charge in
transmembrane segment S4.32 Conversion of this aspartate to
the non-polar glycine residue would prevent this interaction,
potentially impairing regulation of channel opening. These
considerations strongly indicate the pathogenicity of this
mutation.
Further support for the role of this mutation comes from the
closely related sodium channel SCN1A. SCN1A and SCN2A
arose by gene duplication during vertebrate evolution, and retain
87% amino acid sequence identity (1747/2005) with most
divergence in non-transmembrane domains. A de novo mutation
in the corresponding residue of SCN1A, D1608Y, was found in
a patient with severe myoclonic epilepsy of infancy, which
like our patient is characterised by infantile seizures and
intellectual disability.33 Three additional missense mutations
in transmembrane segment D4S3 of SCN1A have been identi-
ﬁed in patients with epilepsy (http://www.molgen.ua.ac.be/
SCN1AMutations/), further demonstrating the pathogenic
potential of this transmembrane segment of the protein.
SCN2A is not routinely included in DNA testing for epilepsy
because mutations of SCN1A are much more common.
Interesting findings
In the remaining six cases, no variants judged as likely to be
causal for most or all features were identiﬁed, although in two
cases one or more interesting candidate variants were found.
Trio 4
Exome sequencing revealed several regions of homozygosity
including several homozygous variants in EFEMP1 (two intronic
SNVs and a 39UTR INDEL), a gene in which heterozygous
mutations are known to cause early onset maculopathies.34e36
Subsequent to this ﬁnding, it was judged that the patient’s
retinal phenotype of bilateral and symmetric distribution of
drusenoid deposits most likely reﬂects dysregulation of the
function of EFEMP1 (E Heon, personal communication). A real-
time reverse transcriptase PCR assay indicated that the level
of EFEMP1 expression in blood is too low to assess any effects
of the variant on controls. This patient also carries a de novo
non-synonymous coding SNV with a PolyPhen score of 0.999 in
the gene ATP6AP2. This gene encodes the (pro)renin receptor
and has multiple functions in the eye, heart, kidney, central
nervous system and other tissues.37e39 This patient highlights
the fact that some subjects who would undergo NGS may very
well have more than one underlying diagnosis, and that all
causative variants may not be detected.
Trio 6
A de novo variant was observed in the 59 consensus splice site
of exon 9 of the HNRNPU gene, which encodes HnRNP U.
This gene is in the critical target region for the seizure pheno-
type of patients with microdeletion of 1q43e44,40 41 a highly
variable syndrome characterised by speech delay, intellectual
disability and seizures. In mice, HnRNP U has been shown to
be linked to preaxial polydactyly caused by abnormal expression
of SHH during limb development,42 and normal HnRNP
U expression is essential for embryonic development.43 We have
been unable to demonstrate a functional effect of the de novo
variant in blood, but it remains possible that it affects expression
of a particular isoform, perhaps in a tissue-speciﬁc manner
during development. In addition, this patient has a de novo
mutation in SMAD1, a gene that partners with SMAD4 in bone
morphogenetic protein signal transduction.44 Given the associ-
ation of de novo SMAD4 mutations with a spontaneous clini-
cally heterogeneous developmental disorder (see above), it is
Figure 2 Expression of TCF4 variant and wild-type (WT) protein in COS-
7 cells. The variant protein (V) is only seen in the presence of proteasome
inhibitors. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
Figure 3 The SCN2A mutation, D1598G, is located in transmembrane
segment 3 of the sodium channel protein domain 4. This residue is
conserved in vertebrate, invertebrate DM (Drosophila) and bacterial
(NaChBac) sodium channels. The D to Y mutation at the corresponding
position of SCN1A was identified in a patient with severe myoclonic
epilepsy (SME) of childhood, an early onset epileptic encephalopathy
with features similar to the affected individual in trio 11 h, human; f, fish.
Figure 1 Expression of endogenous NGLY1 protein in peripheral blood
mononuclear cells from patient, parents and three unrelated healthy
controls. The protein expression level in the patient is less than both parents
and healthy controls. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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possible that mutations in its close partner gene may cause
similar phenotypes.
Interesting variants ultimately considered unlikely to be causal
Trio 2
A synonymous inherited X chromosome variant was found in
the GPM6B gene, which has been considered a good candidate
for causing cases of Pelizaeus-Merzbacher disease.45 Since Peli-
zaeus-Merzbacher Disease had been considered as a diagnosis for
this patient, we tested the cDNA from the trio for possible
effects on splicing, and the DNA from the maternal grandpar-
ents to examine the inheritance. We found that the mutation
had no effect on the cDNA sequence of the patient, and that it
was inherited from the paternal grandfather. This illustrates
the importance of tracking candidate variants through the
relevant pedigree before reaching a judgement concerning
pathogenicity.
Trio 10
This patient has an inherited X chromosome variant predicted
(by Genie46) to affect the 39 splice site of exon 8 of ACSL4, a gene
linked to intellectual disability with absent or severely delayed
speech and dysmorphic facial features.47 However, cDNA
sequencing revealed no differences between the patient and his
parents. Combining this lack of function with a poor ﬁt
between the phenotype of the child and that associated with
known mutations in the gene suggests that this variant unlikely
to be responsible.
For the trios with no likely or suggestive causal variant, we
will perform whole-genome sequencing to screen for variants
that might have been missed by whole-exome sequencing such
as exonic variants that were not captured, or structural variants
not identiﬁable from exome data.
DISCUSSION
This study highlights both the challenges and opportunities in the
application of NGS to clinical diagnosis in patients with intellec-
tual disabilities/congenital anomalies. In cases where we found
a clear and likely cause of the condition, this conclusion depended
on the knowledge of Mendelian diseases associated with the rele-
vant genes. Two of these genes are already well known: TCF4 and
SCN2A; however, the mutations we detected were novel. The
example of EFTUD2 is of very particular interest. Before the recent
identiﬁcation of this gene, a possible case could be made on the
basis of seeing de novo mutations in two of our patients, although
we failed to show a functional effect of one of the two variants in
the available tissue. Subsequent comparison of their phenotypes
revealed a number of similarities. This example shows that
a discovery paradigm focusing on a broad range of conditions
provides an important complement to the more common current
strategy of combining patients with similar conditions on strictly
clinical criteria. By studying the genetics of a broader range of
conditions as we did, it is possible to make a careful assessment of
any phenotypic overlap of patients that have possible causal
mutations in the same genes. In this way, it may be possible to
identify conditions with broader phenotypic presentations than is
possible in the strictly ‘phenotype ﬁrst’ framework. However, we
do note that conﬁrmation that EFTUD2 is causal required its
recent identiﬁcation by Lines and colleagues.7 It is noteworthy that
our study of only 12 patients pointed toward the possibility of
EFTUD2 involvement in two of the cases. If a programme such as
was used here were applied to many hundreds and eventually
thousands of unexplained conditions, it is very plausible that many
new genes would be nominated and conﬁrmed using exactly this
strategy.
Furthermore, information gained from genome sequencing
as described here, focused on a broad range of patients, will likely
expand the phenotypic spectrum of many currently well-known
genetic disorders. Clinical decisions regarding whether or not to
perform a genetic test largely depend on how well the patient
ﬁts the clinical description of the disorder. Although mutations
in TCF4 are known to cause the well described PHS, the patient
in this study did not exhibit two of the most common and
differentiating symptoms of this disorder (periods of hyperven-
tilation and seizures), and although the condition was consid-
ered, the diagnostic yield was not thought to be high enough to
warrant testing. Similarly, the patient with the SMAD4 muta-
tion that is known to cause Myhre syndrome did not show
a typical manifestation of this syndrome. It is possible that there
are many well described genetic conditions in which the vari-
ability in the phenotypic spectrum is not currently appreciated,
and NGS may facilitate considerable broadening of this spec-
trum. The real power of diagnostic sequencing will depend on
establishing very large databases that include mutations of
interest and corresponding phenotypes. For example, intellectual
disabilities and/or congenital abnormalities occur in approxi-
mately 3e4% of children,48 49 and a majority of these are due to
underlying genetic causes, yet close to 50% of children with one
or both of these phenotypes remain undiagnosed.50 51 It is likely
that a high proportion of these undiagnosed cases will start to be
sequenced annually in the next few years, creating the oppor-
tunity for very large databases that will permit the identiﬁ-
cation of currently unrecognised genotype-phenotype
connections.
The suggestive ﬁnding for NGLY1 is also of particular interest.
Rather than being a gene known to be responsible for a
Mendelian disease with phenotypic similarity to the patient
under study, this gene clearly acts in the same pathway as the
known genes causing the Mendelian disorder that had been
considered for the child, that is, a congenital disorder of glyco-
sylation. This case illustrates how we can leverage known
information about the function of a gene, and in particular its
action within a pathway already implicated in Mendelian
disease, to help identify new genetic diagnoses.
Our work also demonstrates the importance of the use of
‘general’, non-gene-speciﬁc functional evaluation of gene
expression to conﬁrm the pathogenicity of a variant. Since the
de novo mutation in TCF4 had not been described before and
involved a splice site, it made a strong but not deﬁnitive case
for causality. Functional studies demonstrated that the mutation
in TCF4 disrupts splicing and results in a protein targeted for
degradation, which conﬁrms causality. This work, therefore,
helps to establish a general paradigm for such clinically moti-
vated sequencing which includes not only the identiﬁcation of
candidate variants but also a generalised function evaluation of
their impact on gene expression and splicing. However, as the
number of sequenced patients increases, and as these data are
increasingly shared in public databases, the need for functional
work for some variants will decrease as the same variants are
shown to occur in multiple patients with similar presentations
(as for the SMAD4 variant in trio 3).
It is also important to emphasise that the paradigm we
adopted in this study is likely to be similar to how NGS would
be applied in clinical genetics practice, since general genetics
clinics would have patients with widely differing phenotypes.
Our study demonstrates the type of patients that would be
sequenced in these clinics and provides data regarding
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expectations of ﬁnding a cause, the importance of functional
assays for probable variants and the value of pre-screening
patients to determine eligibility for NGS. With our inclusion and
exclusion criteria, we set out to maximise the likelihood that
an underlying undiagnosed genetic condition was present in
each of the enrolled patients, and found causal or likely and
interesting variants in 8/12 patients. It is also likely that in
clinical practice, partial explanations would be detected for
diverse manifestation in the same patient, as in trio 4 in our
study, emphasising the complexity of genetic counselling for
such a patient whose manifestations are likely to be due to
more than one underlying genetic cause. Establishing a diag-
nosis is often of value even when a clear change in treatment
is not indicated by the diagnosis. For example, close and
ongoing observation for seizures is now indicated for patient 5
(TCF4), and avoidance of medications that may trigger
seizures, such as antihistamines.52 The family can be
informed that the disorder is due to a de novo variant, and in
the absence of parental mosaicism, other family members are
not at risk, and with future pregnancies the recurrence risk for
the parents is low. Additionally, they can learn about PHS,
have a better idea of future expectations, and reach out for
support from families with similarly affected children. Simi-
larly, patient 11 (SCN2A) should avoid common anti-epileptic
drugs whose primary mechanism is sodium channel inhibition,
since these exacerbate symptoms in patients with SCN1A
mutations.53 A conﬁrmed molecular diagnosis may also protect
patients from incorrect diagnoses that could lead to unhelpful
therapy options.
While cost beneﬁt analyses were not the focus of this work,
it is interesting to note that some of the patients who now have
a genetic diagnosis, underwent many genetic tests prior to
exome sequencing at a considerable estimated cost (eg, more
than $22 000 were spent on laboratory investigations in Trio 2)
While estimating the real costs of exome sequencing is difﬁcult,
it is already clear that in some cases, interrogating genes one by
one or in panels will rapidly lead to greater total costs than
exome or whole-genome sequencing. While these considerations
are encouraging, as is the success rate of six likely genetic diag-
noses out of 12 cases (with one further case likely explained
partially), this work was performed in a research environment
and there will be many challenges involved in a transition to
fully clinically based applications. Itemising those challenges,
from cost and reimbursement to the type and manner of
communication to the families (including the issue of incidental
ﬁndings), is beyond the scope of this work, but we would
highlight two challenges in particular. First, in our experience,
laboratory-based functional analysis is an important part of the
evaluation, and it remains unclear how this would
be incorporated into routine clinical application of NGS, even
as NGS is beginning to be offered by commercial laboratories
as a clinical test. Second, this work required substantial manual
interrogation of both sequence data and candidate genes.
Although variant calling procedures are continually improved
and there are likely to be routines developed to simplify the
process of candidate identiﬁcation,54 it seems likely that for
the foreseeable future, some level of expert judgement will
continue to be required to identify causal mutations from
sequence data, which will contribute to the cost and time of
this type of diagnostics. Currently, it is difﬁcult to imagine how
the level of both variant inspection and functional evaluation
could be provided as part of routine clinical diagnostic testing.
These current essential functions, therefore, present a signiﬁcant
challenge to the use of NGS to provide genetic diagnoses.
Finally, we note that there are a number of reasons that
causal variants may have been missed in some trios in this study.
One important factor is that we do not have a comprehensive
understanding of the function of most genes. For genes whose
function is not well characterised, extensive functional follow-
up may be required to assign causality to a de novo or homo-
zygous variant carried by an individual patient. We may also fail
to detect some causal variants. Exome sequencing does not
capture all exons, nor non-coding regulatory regions, and
structural genomic variants such as CNVs are difﬁcult to
recognise. Additionally, variants within captured regions may
be missed by the mapping/variant-calling algorithms. In the
future, we anticipate this approach will be improved by the
use of whole-genome sequencing and improved variant identi-
ﬁcation, although for the foreseeable future a small proportion
of the genome will remain refractory to high throughout
sequencing. It is also possible that causal variant(s) may exert
their effects through more complex inheritance patterns than
investigated in this study.
In summary, this work indicates that the application of
NGS should be strongly considered in all cases where a genetic
condition is strongly suspected but traditional clinical genetic
testing has proven negative. Furthermore, in some cases at least,
it is likely that NGS will prove faster and less expensive than the
long diagnostic odyssey many families now endure. However,
our work, like that of others, offers the cautionary note that
it will probably be possible to identify very strong candidate
variants in any sequenced genome and that further studies
such as functional assays or multiple patients with mutations
in the same gene will often be needed to establish causality.
Considerable attention must be paid to establishing appropriate
standards of evidence before the results of NGS are used to
inﬂuence patient care, and establishing such standards will be
a major challenge for NGS in the clinic.
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